Abeona Therapeutics (ABEO) Non-Current Debt (2018 - 2026)

Abeona Therapeutics' Non-Current Debt history runs 8 years deep, the most recent figure standing at $4.8 million for Q1 2026.

• In Q1 2026, Non-Current Debt fell 57.32% year-over-year to $4.8 million; the TTM figure through Mar 2026 stood at $4.8 million (down 57.32% YoY), while the FY2025 annual figure was $7.8 million, down 40.07% from the prior year.
• Non-Current Debt for Q1 2026 stood at $4.8 million, down from $7.8 million in the prior quarter.
• The five-year high for Non-Current Debt was $18.1 million in Q1 2024, with the low at $3.9 million in Q1 2022.
• The 4-year median for Non-Current Debt is $10.9 million (2025), against an average of $9.7 million.
• The sharpest annual moves came in 2022 and 2026: Non-Current Debt surged 224.15% in 2022, then sank 57.32% in 2026.
• Abeona Therapeutics' Non-Current Debt stood at $4.2 million in 2022, then soared by 213.16% to $13.0 million in 2024, then plunged by 40.07% to $7.8 million in 2025, then plunged by 39.15% to $4.8 million in 2026.
• Business Quant data shows ABEO's Non-Current Debt at $4.8 million in Q1 2026, $7.8 million in Q4 2025, and $10.9 million in Q3 2025.